Estramustine Phosphateの臨床的評価

Abstract

The clinical effects of estramustine phosphate on prostatic cancer were evaluated in ten patients. Seven patients of them were administered with estramustine phosphate as primary treatment (group A) and the others had been previously treated with anti-androgen treatment with unsatisfactory results (group B). The clinical effects were judged from improvement of objective and/or subjective symptoms. The clinical responses were observed in 6 of the 7 patients in group A, and 2 of the 3 patients in group B. Side effects were observed in 4 patients. We noticed gastrointestinal disturbances, hepatic function abnormal, gynecomastia and chest pain as side effects. We concluded from this clinical trial that, oral estramustine phosphate showed good clinical effects in patients with prostatic cancer.